Soft Tissue Tumors Therapeutics
1. Ogsiveo patent expiration
Treatment: Treatment of adult patients with progressing desmoid tumors
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10941118 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| US10710966 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| US11845732 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| US7795447 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2030
(4 years from now) | |
| US7951958 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Mar, 2025
(9 months ago) | |
| US7342118 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2025
(4 months ago) | |
| US10590087 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11612588 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(16 years from now) | |
| US11844780 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(16 years from now) | |
| US12011434 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US12138246 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US11957662 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US11951096 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US11925620 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US11925619 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US11938116 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US11807611 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(16 years from now) | |
| US12011435 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US12036207 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US11872211 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(17 years from now) | |
| US12247012 | SPRINGWORKS | Synthesis of nirogacestat |
Jul, 2042
(16 years from now) | |
| US11884635 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| US11820748 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| US12110277 | SPRINGWORKS | Synthesis of nirogacestat |
Jul, 2042
(16 years from now) | |
| US11504354 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(16 years from now) | |
| US11905255 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| US12116347 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| US12234210 | SPRINGWORKS | Synthesis of nirogacestat |
Jul, 2042
(16 years from now) | |
| US11884634 | SPRINGWORKS | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
Aug, 2039
(13 years from now) | |
| US12297177 | SPRINGWORKS | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
Aug, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
| ODE*(ODE*) | Nov 27, 2030 |
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Dosage: TABLET
More Information on Dosage
OGSIVEO family patents
2. Turalio patent expiration
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8404700 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(1 year, 10 months from now) | |
| US10730876 | DAIICHI SANKYO INC | Synthesis of a compound that modulates kinases |
May, 2036
(10 years from now) | |
| US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(7 years from now) | |
| US8722702 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(1 year, 10 months from now) | |
| US9802932 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(10 years from now) | |
| US9169250 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(7 years from now) | |
| US8461169 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity |
Apr, 2028
(2 years from now) | |
| US10189833 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(10 years from now) | |
| US10961240 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(12 years from now) | |
| US10941142 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(12 years from now) | |
| US10435404 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Dosage: CAPSULE
More Information on Dosage
TURALIO family patents